Company No:
Contents
| Note | 31.05.2025 | |
| £ | ||
| Fixed assets | ||
| Intangible assets | 3 |
|
| 66,775 | ||
| Current assets | ||
| Debtors | 4 |
|
| Cash at bank and in hand |
|
|
| 94,774 | ||
| Creditors: amounts falling due within one year | 5 | (
|
| Net current liabilities | (12,441) | |
| Total assets less current liabilities | 54,334 | |
| Net assets |
|
|
| Capital and reserves | ||
| Called-up share capital | 6 |
|
| Profit and loss account |
|
|
| Total shareholders' funds |
|
Directors' responsibilities:
The financial statements of Technica Pharmaceuticals Limited (registered number:
|
M M C Nahab
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.
Technica Pharmaceuticals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Boldrewood Farm, Lenham, Maidstone, Kent, England, ME17 2LT, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
Exchange differences are recognised in the Statement of Comprehensive Income in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
| Trademarks, patents and licences |
|
| Website costs |
|
| Period from 09.12.2023 to 31.05.2025 |
|
| Number | |
| Monthly average number of persons employed by the Company during the period, including directors |
|
| Trademarks, patents and licences |
Website costs | Total | |||
| £ | £ | £ | |||
| Cost | |||||
| At 09 December 2023 |
|
|
|
||
| Additions |
|
|
|
||
| At 31 May 2025 |
|
|
|
||
| Accumulated amortisation | |||||
| At 09 December 2023 |
|
|
|
||
| Charge for the financial period |
|
|
|
||
| At 31 May 2025 |
|
|
|
||
| Net book value | |||||
| At 31 May 2025 |
|
|
|
| 31.05.2025 | |
| £ | |
| Amounts owed by Group undertakings |
|
| Amounts owed by directors |
|
| VAT recoverable |
|
|
|
| 31.05.2025 | |
| £ | |
| Trade creditors |
|
| Corporation tax |
|
| Other creditors |
|
|
|
| 31.05.2025 | |
| £ | |
| Allotted, called-up and fully-paid | |
|
|
|